市場調査レポート

抗糖尿病薬市場分析:製品別 (インスリン、ビグアニド、チアゾリジンジオン、GLP作動薬、スルホニル尿素、DPP-4阻害剤、SGLT-2、αグルコシダーゼ阻害剤、メグリチニド)、および2020年までのセグメント予測

Antidiabetics Market Analysis By Product (Insulin, Biguanides, Thiazolodinediones, GLP-agonists, Sulphonylureas, DPP-4 inhibitors, SGLT-2, Alpha-glucosidase Inhibitors, Meglitinides) And Segment Forecasts To 2020

発行 Grand View Research, Inc. 商品コード 342330
出版日 ページ情報 英文 75 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
抗糖尿病薬市場分析:製品別 (インスリン、ビグアニド、チアゾリジンジオン、GLP作動薬、スルホニル尿素、DPP-4阻害剤、SGLT-2、αグルコシダーゼ阻害剤、メグリチニド)、および2020年までのセグメント予測 Antidiabetics Market Analysis By Product (Insulin, Biguanides, Thiazolodinediones, GLP-agonists, Sulphonylureas, DPP-4 inhibitors, SGLT-2, Alpha-glucosidase Inhibitors, Meglitinides) And Segment Forecasts To 2020
出版日: 2015年01月01日 ページ情報: 英文 75 Pages
概要

世界の抗糖尿病薬市場は2020年までに841億3,000万米ドルに達すると予測されています。インスリンが最も収益を上げるセグメントで、2013年には200億米ドルを占めました。アジア太平洋地域やラテンアメリカ市場などの未開拓市場が将来の市場の成長を牽引すると期待されています。

当レポートでは、世界の抗糖尿病薬市場について分析し、市場の現状と製品見通し、地域別動向などをまとめています。

第1章 エグゼクティブサマリー

第2章 抗糖尿病薬業界見通し

  • 市場セグメンテーション
  • 市場規模と成長見通し
  • 市場動向
    • 促進因子
    • 阻害因子
  • 優先される機会
  • 業界分析
  • PESTEL分析
  • パイプライン概要

第3章 製品見通し

  • 製品別市場シェア:2013年、2020年
  • インスリン
  • その他の抗糖尿病薬
  • αグルコシダーゼ阻害剤
  • スルホニル尿素
  • ビグアニド
  • GLP1作動薬
  • DPP-4阻害剤
  • メグリチニド
  • SGLT-2
  • チアゾリジンジオン

第4章 地域別見通し

  • 地域別市場シェア:2013年、2020年
  • 北米
  • 欧州
  • アジア太平洋地域
  • その他の諸国

第5章 競合環境

  • Sanofi Aventis
  • 武田薬品工業株式会社
  • Eli Lilly
  • Oramed Pharmaceuticals Inc.
  • Merck & Co. Inc.
  • Novo Nordisk
  • Bristol-Myers Squibb
  • Halozyme Therapeutics
  • Pfizer ?5.9.1. Company Overview

第6章 調査方法と調査範囲

図表

目次

Global antidiabetics market is expected to reach USD 84.13 billion by 2020. Growing prevalence of diabetes is the primary driver of this market. Growth in prevalence of disease causing lifestyle disorders such as irregular dietary habits and obesity is also expected to boost product demand by triggering incidence rates of target diseases. Future commercialization of products currently in the pipeline and the presence of large untapped opportunities in the emerging Asia Pacific and Latin American markets is expected to fuel future market growth.

Insulin was the most revenue generating segment and its market was valued at over USD 20.0 billion in 2013. Insulin is also one of the most lucrative segments of this market. Introduction of new products exhibiting higher efficacy coupled with the presence of favorable government initiatives are some factors attributing to its market attractiveness.

Further key findings from the study suggest:

Long acting insulin was the leading product segment in 2013 and is expected to grow at the CAGR of over 15.0% during the forecast period. The introduction of advanced products, high prices associated with these products and the phasing out of human insulin are some key factors attributing for its large share.

Rapid uptake of newly approved DPP-4 inhibitors such as Januvia, Nesina and Onglyza on account of their once daily dosage regimens and safety profiles catalyzed the growth of this market.

North America was the most matured antidiabetics market in 2013 accounting for over 43.0% of the market High market penetration of insulin and other antidiabetics and the presence of sophisticated reimbursement framework are expected to drive regional market growth.

Asia Pacific is expected to present manufacturers with lucrative future growth opportunities. Large presence of unmet patient needs and rapidly improving healthcare infrastructure are some factors expected to drive market growth in the region. The market is also expected to be driven by the introduction of cheaper products made available by local manufacturers.

Some key market players of antidiabetics include Sanofi Aventis, Takeda Pharmaceuticals, Eli Lilly, Oramed Pharmaceuticals Inc., Merck & Co. Inc., Novo Nordisk, Bristol-Myers Squibb, Halozyme Therapeutics and Pfizer.

The market is oligopolistic in nature with few players accounting for over 70% of the market. Extensive R&D investments aimed at new product development and entering new markets via government contracts are the key sustainability strategies adopted by these organizations.

For the purpose of this study, Grand View Research has segmented the global antidiabetics market on the basis of product and region:

Global Insulin Product Outlook (Revenue, USD Million, 2012 - 2020)

  • Rapid acting
  • Long acting
  • Premixed
  • Premixed analog
  • Short acting
  • Intermediate acting

Global Antidiabetics Product Outlook (Revenue, USD Million, 2012 - 2020)

  • Alpha-glucosidase inhibitors
  • Biguanides
  • Sulphonylureas
  • GLP-1 agonist
  • Meglitinides
  • DPP-4 inhibitors
  • SGLT - 2
  • Thiazolodinediones

Antidiabetics Regional Outlook (Revenue, USD Million, 2012 - 2020)

  • North America
  • Europe
  • Asia Pacific
  • RoW

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Antidiabetics- Industry Summary and Critical Success Factors (CSFs)

Chapter 2. Antidiabetics Industry Outlook

  • 2.1. Market Segmentation
  • 2.2. Market size and growth prospects
  • 2.3. Antidiabetics - Market dynamics
    • 2.3.1. Market driver analysis
      • 2.3.1.1. Growing prevalence of diabetes
      • 2.3.1.2. Presence of a strong product pipeline portfolio
      • 2.3.1.3. Growing prevalence of lifestyle induced disorders such as obesity
    • 2.3.2. Market Restraint Analysis
      • 2.3.2.1. High insulin prices
  • 2.4. Key Opportunities Prioritized
  • 2.5. Industry Analysis - Porter's
  • 2.6. Antidiabetics - PESTEL analysis
  • 2.7. Antidiabetics market - Pipeline overview

Chapter 3. Antidiabetics Product Outlook

  • 3.1. Antidiabetics market share by product, 2013 & 2020
  • 3.2. Insulin
    • 3.2.1. Insulin market share, by product, 2013 & 2020
    • 3.2.2. Rapid acting analog market
      • 3.2.2.1. Rapid acting analog market, 2012 - 2020 (USD Million)
    • 3.2.3. Long acting analog market
      • 3.2.3.1. Long acting analog market, 2012 - 2020 (USD Million)
    • 3.2.4. Premixed analog market
      • 3.2.4.1. Premixed analog market, 2012 - 2020 (USD Million)
    • 3.2.5. Premixed insulin market
      • 3.2.5.1. Premixed insulin market, 2012 - 2020 (USD Million)
    • 3.2.6. Short acting insulin market
      • 3.2.6.1. Short acting insulin market, 2012 - 2020 (USD Million)
    • 3.2.7. Intermediate acting insulin market
      • 3.2.7.1. Intermediate acting insulin market, 2012 - 2020 (USD Million)
  • 3.3. Other antidiabetics
  • 3.4. Alpha glucosidase inhibitors
    • 3.4.1. Alpha glucosidase inhibitors market, 2012 - 2020 (USD Million)
  • 3.5. Biguanides
    • 3.5.1. Biguanides market, 2012 - 2020 (USD Million)
  • 3.6. Sulphonylureas
    • 3.6.1. Sulphonylureas market, 2012 - 2020 (USD Million)
  • 3.7. GLP 1 (Glucagon like peptide) agonists
    • 3.7.1. GLP 1 agonist market, 2012 - 2020 (USD Million)
  • 3.8. DPP - 4 (Dipeptyl peptides) inhibitors
    • 3.8.1. DPP-4 market, 2012 - 2020 (USD Million)
  • 3.9. Meglitinides
    • 3.9.1. Meglitinides market, 2012 - 2020 (USD Million)
  • 3.10. SGLT - 2 (sodium glucose transport proteins) inhibitors
    • 3.10.1. SGLT - 2 inhibitors market, 2012 - 2020 (USD Million)
  • 3.11. Thiazolodinediones
    • 3.11.1. Thiazolodinediones market, 2012 - 2020 (USD Million)

Chapter 4. Antidiabetics Regional Outlook

  • 4.1. Antidiabetics market share, by region, 2013 & 2020
  • 4.2. North America antidiabetics market
    • 4.2.1. North America antidiabetics market, 2012 - 2020 (USD Million)
  • 4.3. Europe antidiabetics market
    • 4.3.1. Europe antidiabetics market, 2012 - 2020 (USD Million)
  • 4.4. Asia Pacific antidiabetics market
    • 4.4.1. Asia Pacific antidiabetics Market, 2012 - 2020 (USD Million)
  • 4.5. RoW antidiabetics market
    • 4.5.1. RoW antidiabetics market, 2012 - 2020 (USD Million)

Chapter 5. Competitive Landscape

  • 5.1. Sanofi Aventis
    • 5.1.1. Company Overview
    • 5.1.2. Financial Performance
    • 5.1.3. Product Benchmarking
    • 5.1.4. Strategic Initiatives
  • 5.2. Takeda Pharmaceuticals
    • 5.2.1. Company Overview
    • 5.2.2. Financial Performance
    • 5.2.3. Product Benchmarking
    • 5.2.4. Strategic Initiatives
  • 5.3. Eli Lilly
    • 5.3.1. Company Overview
    • 5.3.2. Financial Performance
    • 5.3.3. Product Benchmarking
    • 5.3.4. Strategic Initiatives
  • 5.4. Oramed Pharmaceuticals Inc.
    • 5.4.1. Company Overview
    • 5.4.2. Financial Performance
    • 5.4.3. Product Benchmarking
    • 5.4.4. Strategic Initiatives
  • 5.5. Merck & Co. Inc.
    • 5.5.1. Company Overview
    • 5.5.2. Financial Performance
    • 5.5.3. Product Benchmarking
    • 5.5.4. Strategic Initiatives
  • 5.6. Novo Nordisk
    • 5.6.1. Company Overview
    • 5.6.2. Financial Performance
    • 5.6.3. Product Benchmarking
    • 5.6.4. Strategic Initiatives
  • 5.7. Bristol-Myers Squibb
    • 5.7.1. Company Overview
    • 5.7.2. Financial Performance
    • 5.7.3. Product Benchmarking
    • 5.7.4. Strategic Initiatives
  • 5.8. Halozyme Therapeutics
    • 5.8.1. Company Overview
    • 5.8.2. Financial Performance
    • 5.8.3. Product Benchmarking
    • 5.8.4. Strategic Initiatives
  • 5.9. Pfizer
    • 5.9.1. Company Overview
    • 5.9.2. Financial Performance
    • 5.9.3. Product Benchmarking
    • 5.9.4. Strategic Initiatives

Chapter 6. Methodology and Scope

  • 6.1. Research Methodology
  • 6.2. Research Scope & Assumptions
  • 6.3. List of Data Sources

List of Tables

  • 1. Antidiabetics - Industry Summary & Critical Success Factors (CSFs)
  • 2. Global insulin market, by product, 2012 - 2020 (USD Million)
  • 3. Global other antidiabetics market, by product, 2012 - 2020 (USD Million)
  • 4. Global antidiabetics market, by region, 2012 - 2020 (USD Million)
  • 5. Antidiabetics - Key market driver analysis
  • 6. North America diabetes prevalence (national prevalence %), 2013 & 2035
  • 7. Europe diabetes prevalence (national prevalence %), 2013 & 2035
  • 8. Latin America diabetes prevalence (national prevalence %), 2013 & 2035
  • 9. MENA and Africa diabetes prevalence (national prevalence %), 2013 & 2035
  • 10. CIS diabetes prevalence (national prevalence %), 2013 & 2035
  • 11. Asia Pacific diabetes prevalence (national prevalence %), 2013 & 2035
  • 12. Antidiabetics - Key market restraint analysis
  • 13. Antidiabetics market - Pipeline overview
  • 14. Insulin types and brands
  • 15. List of brands of alpha glucosidase for diabetes
  • 16. List of major brands of biguanides for diabetes
  • 17. Brands and generic names of sulphonylureas for diabetes
  • 18. Brands and generic names of GLP-1 for diabetes
  • 19. List of major brands of DPP-4 for diabetes
  • 20. List of major drugs of meglitinides for diabetes
  • 21. List of major drugs of SGLT-2 for diabetes
  • 22. North America insulin market, by product, 2012 - 2020 (USD Million)
  • 23. North America insulin market, by application, 2012 - 2020 (USD Million)
  • 24. North America other antidiabetics market, by product, 2012 - 2020 (USD Million)
  • 25. Europe insulin market, by product, 2012 - 2020 (USD Million)
  • 26. Europe insulin market, by application, 2012 - 2020 (USD Million)
  • 27. Europe other antidiabetics market, by product, 2012 - 2020 (USD Million)
  • 28. Asia Pacific insulin market, by product, 2012 - 2020 (USD Million)
  • 29. Asia Pacific insulin market, by application, 2012 - 2020 (USD Million)
  • 30. Asia pacific other antidiabetics market, by product, 2012 - 2020 (USD Million)
  • 31. RoW insulin market, by product, 2012 - 2020 (USD Million)
  • 32. RoW insulin market, by application, 2012 - 2020 (USD Million)
  • 33. RoW other antidiabetics market, by product, 2012 - 2020 (USD Million)

List of Figures

  • 1. Antidiabetics market segmentation
  • 2. Global antidiabetics market revenue, 2012 - 2020 (USD Million)
  • 3. Antidiabetics: Market dynamics
  • 4. Diabetes prevalence of top 10 countries in 2013 in the age group of 20 to 79 years (million)
  • 5. Current and projected prevalence of diabetes, by geography, 2013 & 2035 (% increase)
  • 6. Key opportunities prioritized
  • 7. Antidiabetics market - Porter's analysis
  • 8. Antidiabetics market - PESTEL analysis
  • 9. Antidiabetics market share by product, 2013 & 2020
  • 10. Insulin market share by product, 2013 & 2020
  • 11. Rapid acting analog market, 2012 - 2020 (USD Million)
  • 12. Long acting analog market, 2012 - 2020 (USD Million)
  • 13. Premixed analog market, 2012 - 2020 (USD Million)
  • 14. Premixed insulin market, 2012 - 2020 (USD Million)
  • 15. Short acting insulin market, 2012 - 2020 (USD Million)
  • 16. Intermediate acting insulin market, 2012 - 2020 (USD Million)
  • 17. Global alpha glucosidase inhibitors market, 2012 - 2020 (USD Million)
  • 18. Global biguanides market, 2012 - 2020 (USD Million)
  • 19. Global sulphonylureas market, 2012 - 2020 (USD Million)
  • 20. Global GLP 1 agonist market, 2012 - 2020 (USD Million)
  • 21. Global DPP-4 market, 2012 - 2020 (USD Million)
  • 22. Global meglitinides market, 2012 - 2020 (USD Million)
  • 23. Global SGLT - 2 inhibitors market, 2012 - 2020 (USD Million)
  • 24. Global thiazolodinediones market, 2012 - 2020 (USD Million)
  • 25. Antidiabetics market share by region, 2013 & 2020
  • 26. North America antidiabetics market, 2012 - 2020 (USD Million)
  • 27. Europe antidiabetics market, 2012 - 2020 (USD Million)
  • 28. Asia Pacific antidiabetics market, 2012 - 2020 (USD Million)
  • 29. RoW antidiabetics market, 2012 - 2020 (USD Million)
Back to Top